Haibu Medicine has bπ→een recognized as a 'Beijing →πIntellectual Property Pilot U¶♦÷≈nit'.

Technology-driven development leads theα£™π way, technological innovation lights €≈←εup the future. Let's takΩ>e a look at the technolog∑'ical achievements the com♣↑pany has made in recent yea​↓rs~

Research and Development Platform Con<$γ‌struction

Three major R&D platforms→&± of Haibu Pharmaceutical

• Haibu Pharmaceutical has estab®≈♦∞lished three major R&am"σp;D platforms: 'Active Phσφ★armaceutical Ingredie'∞‌‍nt R&D, Formulation R&am∑×≠p;D, and Innovation & Improvement∞★↕∑' based on actual management and→ ≥ customer needs. Each platform is indβ≠ependently managed according ™δδ★to the type of business it un±₩dertakes, with unified allocat™≥"ion of R&D resources>≤↔ by the company for collabo§™αrative development.
• The company has been awarde↕≥d honors such as Natioφσnal High-tech Enterprise, CNAS Labor₽σαatory Accreditation Certificate←™≤ from China National Ac≈♠creditation Service for Conform♦φity Assessment, and Beijing Sci®φence and Technology Research and >σDevelopment Institution, and ha≠✘s been ranked among the '→$αTop 20 Pharmaceutical R&α¥♠​D Companies in China' for many year↑♥←s.

Intellectual Property Manage↕∞​ment
      Formed a unique intellectual ♦♠₽λproperty management system at Haibu.

• Established an Infor™ mation and Intellectual ≠  Property Department to‍≠ actively promote technology inn€¥"<ovation management and prote§←λction, conduct patent mini"σng and drafting of patent appli≈£☆÷cation documents, track progress on pa↓​tent submission, acceptance,®   payment, authorization regist​εΩration work, establi↓✔₹sh patent registration ledg✔∞€ers and archives, and maintain patent∑↔s effectively.
• Established an intellectual prΩ£<operty reward system to reward in↔'↓↕ventors according to the s♣'ystem to stimulate the ent  husiasm of scientific research perso"↑nnel for invention and creation.

Technology Achievement Transfor"∞€£mation

• (Haibu Pharmaceutical) has obtained↓↔★ more than 70 clinical productioδ ¥βn licenses and new drug certifiα<cates approved by China's ≠&σ♠National Medical Products A₩÷♥Ωdministration.
• (It) has submitted mo™¥αre than ten international re✔≈‍•gistration applications to FDA, EU≈&, etc., achieving over one hu÷₽‍ndred technology transfers to §'€client companies cumulatively.
• (It) has completed multip←  le technology achievement transformati©↕∏ ons with over thirty seriesλπ¶φ products achieving commercial p‌↑roduction.